Cardiovascular disease (CVD) risk equations are useful to guide treatment decisions for blood pressure and lipid-lowering medications because they identify patients who are at high risk of CVD but do not have either blood pressure or cholesterol measurements above the levels when considering treatment as [...]
Hypertensive disorders of pregnancy (HDP) affect up to 10% of all pregnancies annually and are associated with an increased risk of maternal and fetal morbidity and mortality. This guideline represents an update of the Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) guidelines for [...]
The VALID BP project was initiated to increase the availability of validated blood pressure measuring devices (BPMDs). The goal is to eliminate non validated BPMDs and minimise over- and underdiagnosis of hypertension caused by inaccurate readings. This study was undertaken to assess the potential return [...]
Hypertrophic cardiomyopathy (HCM) is the commonest genetic cardiomyopathy world-wide, affecting approximately 1 in 500 individuals. Current therapeutic interventions comprise lifestyle optimisation, medications, septal reduction therapies and rarely cardiac transplantation. Advances in our understanding of disease-causing genetic variants in HCM and their associated molecular mechanisms have [...]
Quality use of anti-hypertensive and cholesterol-lowering medications is crucial for successful cardiovascular disease management. This systematic review aimed to estimate levels of over and underuse of services for primary and secondary prevention of cardiovascular diseases from 2000 to 2020
The aim of this study was to evaluate the cost effectiveness of ambulatory blood pressure monitoring (ABPM) compared with home blood pressure monitoring (HBPM) and clinic blood pressure monitoring (CBPM) in diagnosing hypertension in Australia.
Overdiagnosis causes well people to be labelled as abnormal or diseased with possible adverse psychosocial and financial consequences, and usually results in overtreatment with possible physical harms. It may occur because of overdetection because of increased sensitivity of a new test, and/or overdefinition because of [...]